| Types | DnaRegion
|
| Roles | polypeptide_domain
Protein_Domain
|
| Sequences | BBa_K1781002_sequence (Version 1)
|
Description
ZHER2 was one of the first affibodies created and it binds to the Human Epidermal Growth Factor 2 (HER2). They originate from mutations in the Immunoglobin G Binding Domain of Protein A from Staphylococcus aureus. Affibodies are engineered to bind to larger proteins or peptides where they imitate monoclonal antibodies. They are used in a multitude of therapies in biotechnology to bioimaging. ZHER2 can particular be used as a protein-protein interaction tool, as well as a way to verify antibody interactions as it binds to the cytoplasmic domain of HER2 at a different epitope than the antibodies.
Notes
As it is only 58 amino acids long, the small size of the sequence can be problematic towards cloning and recombineering procedures
Source
The sequence was received from the scientific paper by Charles Eigenbrot in 2010, who engineered ZHER2 to have a better affinity towards HER2.
